Photo of Jessica M. Clement, M.D.

Jessica M. Clement, M.D.

Associate Professor of Medicine
Academic Office Location:

UConn Health
263 Farmington Avenue
Farmington, CT 06030
Phone: 800-579-7822
860-679-2100
Website(s):

Neag Comprehensive Cancer Center

  • Looking for a Physician?

    This faculty member is also
    a practicing physician at UConn Health.

    Learn more >

Dr. Clement is an assistant professor of medicine in the Division of Hematology/Oncology and Neag Comprehensive Cancer Center. She specializes in the treatment of genitourinary (bladder, prostate, kidney, testicular) and gastrointestinal cancers.

Education
DegreeInstitutionMajor
B.S.Union CollegeBiology
M.D.Virginia Commonwealth UniversityMedicine

Post-Graduate Training
TrainingInstitutionSpecialty
InternshipBeth Israel Deaconess Medical CenterMedicine
ResidencyBeth Israel Deaconess Medical CenterMedicine
Chief ResidentBeth Israel Deaconess Medical CenterChief Resident, Internal Medicine
FellowshipBeth Israel Deaconess Medical CenterHematology/Oncology

Awards
Name of Award/HonorAwarding Organization
Association of American Medical Colleges (AAMC) Leadership Education and Development (LEAD) Certificate Program Fellow, Northeast Group on Educational Affairs (NEGEA) Cohort
Connecticut Magazine "Top Doc" for Oncology & Hematology

Genitourinary malignancies (bladder, prostate, kidney and testicular cancers).

Name & DescriptionCategoryRoleTypeScopeStart YearEnd Year
Ron Foley Foundation Medical Advisory BoardCommunity ServiceExternalLocal2017
Speaker/Participant, UConn Football 101 ClinicCommunity ServiceUConn-StorrsLocal2017
Bladder Cancer, ad hocAdvisory CommitteeExternalInternational2017
Honor Board Advisory CommitteeAdvisory CommitteeAdvisoryUConn HealthLocal2017
Liaison Committee on Medical Education (LCME) Student Sub-Committee, Medical Student StandardsEducation CommitteeLiaisonUConn HealthLocal2017
Interviewer, Medical School AdmissionsEducation CommitteeInterviewerUConn HealthLocal2016
Hematology-Oncology Utilization Review CommitteeProfessional/Scientific OrganizationReviewerExternalNational2015
Hematology-Oncology Utilization Review Committee, Pharmacy Policy Subcommittee for large national health planOtherReviewerExternalNational2015
Society of Urologic Oncology, Affiliate MemberProfessional/Scientific OrganizationMemberExternalNational2014
Bladder Cancer Advocacy Network Travel GrantsOtherJournal and Grants ReviewerInternational2014
Leo and Anne Albert Institute for Bladder Cancer Care and Research, Member of Board of DirectorsResearch CommitteeExternalNational2014
European UrologyProfessional/Scientific JournalReviewerExternalInternational2013
Journal of Translational MedicineProfessional/Scientific JournalReviewerExternalNational2012
Hematology/Oncology Fellowship Selection CommitteeAdvisory CommitteeMemberUConn HealthLocal2012
University of Connecticut Health Center: Chemotherapy CommitteeProfessional/Scientific OrganizationMemberUConn HealthUniversity2010
Connecticut Medical SocietyProfessional/Scientific OrganizationMemberExternalState2010
American Society of Clinical OncologyProfessional/Scientific OrganizationMemberExternalNational2006
Massachusetts Medical SocietyProfessional/Scientific OrganizationMemberExternalNational2002

Dr. Clement is involved in bladder cancer research with Dr. John Taylor in the Division of Urologic Oncology.

Journal Articles

Book Chapters

  • Chapter 130 Colorectal Cancer
    Holle LM, Clement JM, Davis LE. Pharmacotherapy: A Pathophysiologic Approach
  • Pharmacotherapy: A Pathophysiologic Approach Chapter 130 Colorectal Cancer
    Holle LM, Clement JM, Davis LE 10th Edition 2017 McGraw Hill Education

Abstracts

  • Carbonic Anhydrase IX (CA IX) and Pathologic Features as Predictors of Outcome in Patients with Metastatic Renal Cell Carcinoma (mRCC) Receiving VEGF-Targeted Therapy
    T.K. Choueiri, M.M. Regan, A.J. Brick, J.M. Clement, C. Kwabi, K. Shah, A. Amato, D.F. McDermott, M.B. Atkins, S. Signoretti Journal of Clinical Oncology: 2008 ASCO Annual Meeting Proceedings 26(15S):674s
  • Evaluation of the clinical activity of ipilimumab (IPI) plus nivolumab (NIVO) in patients (pts) with NIVO-refractory metastatic urothelial cancer (UC).
    Callahan MK, Kania BE, lyer G, Clement JM, Funt S, McCoy AS, Hettich G, Ziv E, Bluth MJ, Wong, P, Wolchok JD, Bajorin DF, Rosenberg JE Journal of clinical Oncology, 35 2017 (supl 6S; abstract 384)
  • Patients with Metastatic Renal Cell Carcinoma (mRCC) Receiving Sunitinib in “Real-World” Clinical Practice: Baseline Characteristics and Treatment Efficacy
    J.M. Clement, D.F. McDermott, T.K. Choueiri, A.J. Brick, C. Kwabi, K. Shah, J.R. Weiner, M.S. Duh, M.P. Neary, W.K. Oh Supplement to Journal of Clinical Oncology: 2008 ASCO Annual Meeting Proceedings 26(15S):676s

Case Reports

Other

  • Interview - What is Appropriate Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer? A Conversation with Jessica J. Clement, M.D.
    By Caroline Helwick The American Society of Clinical Oncology Post 2017 May;
Title or AbstractTypeSponsor/EventDate/YearLocation
Conference, How to give a PowerPoint TalkLectureUConn2017UConn
Genitourinary Medical Oncology ReviewLectureUConn2017
Conference, Urology Journal ClubLectureUConn2017
Principles of Cancer Treatment IILectureUConn2017
The Evolving Role of Genomics in Cancer: Breast Cancer the Pioneer; Bladder Cancer the NewcomerLectureUConn/Mini Med School2017UConn